IP Library › Granted Patent US 6,919,323
Granted Patent B2
US 6,919,323 · App. 10/194,028 · Granted Jul 19, 2005

Pyridazinone inhibitors of fatty acid binding protein and method

Assignee: Bristol-Myers Squibb Company
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,919,323
App. No.
10/194,028
Granted
Jul 19, 2005
Kind
B2
Abstract

aP2 inhibiting compounds are provided having the formula wherein A, X, R and Z are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing such aP2 inhibitors alone or in combination with other therapeutic agents, including other antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin.

Claims (22)

1. A compound of formula I

enantiomers, diastereomers, pharmaceutically acceptable salts thereof, prodrug esters thereof wherein

R is —(CR 3 R 4 ) n -J, where n is 1 and R 3 and R 4 are the same or different and are selected from hydrogen, alkyl or substituted alkyl;

J is an aryl group having 6-10 carbon atoms optionally independently substituted with one or more halogen;

A is methylene or methylene-oxy;

X is —CO 2 R 9 , tetrazole, —C(NH)NHOH, —PO 3 R 9 R 10 , or —CONHOH; and

Z is an aryl group having 6-10 carbon atoms optionally independently substituted with one or more alkyl and or halogen;

R 9 is H or alkyl; and

R 10 is H or alkyl.

2. A compound of claim 1 wherein

R is —(CR 3 R 4 ) n -J, where n is 1 and R 3 and R 4 are each hydrogen;

J is optionally substituted phenyl;

A is methylene;

X is —CO 2 R 9 , or tetrazole; and

Z is optionally substituted phenyl.

3. The compound of claim 2 wherein J is phenyl independently substituted with one or more halogen.

4. The compound of claim 2 wherein Z is phenyl independently substituted with one or more alkyl or halogen.

5. The compound of claim 2 wherein X is —CO 2 R 9 .

6. The compound of claim 5 wherein R 9 is hydrogen or alkyl.

7. A pharmaceutical composition comprising at least one compound of claim 1 together with a pharmaceutically acceptable vehicle or carrier therefor.

8. A method for treating diabetes, insulin resistance, hyperglycemia, hyperinsulinemia, or elevated blood levels of free fatty acids or glycerol, obesity, hypertriglyceridemia, inflammation, atherosclerosis, diabetic retinopathy, diabetic neuropathy or diabetic nephropathy which comprises administering to a mammalian species in need thereof an effective amount of a compound of claim 1 .

9. A method for treating diabetes, insulin resistance, hyperglycemia, hyperinsulinemia, or elevated blood levels of free fatty acids or glycerol, obesity, hypertriglyceridemia, inflammation, atherosclerosis, diabetic retinopathy, diabetic neuropathy or diabetic nephropathy which comprises administering to a mammalian species in need thereof an effective amount of a compound of claim 2 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 12, 2002
From: SULSKY, RICHARD; ROBL, JEFFREY A.
To: BRISTOL-MYERS SQUIBB COMPANY
Reel/Frame 013116/0201 →
Continuity (2)
Provisional Application 6030535600 · Jul 13, 2001
Related Publication 20030040516A1 · Feb 27, 2003